BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35931701)

  • 21. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
    Dodd RL; Slevin NJ
    Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.
    Ivanov SV; Panaccione A; Brown B; Guo Y; Moskaluk CA; Wick MJ; Brown JL; Ivanova AV; Issaeva N; El-Naggar AK; Yarbrough WG
    Oncogene; 2013 Aug; 32(32):3698-710. PubMed ID: 23027130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenoid cystic carcinoma: emerging role of translocations and gene fusions.
    Wysocki PT; Izumchenko E; Meir J; Ha PK; Sidransky D; Brait M
    Oncotarget; 2016 Oct; 7(40):66239-66254. PubMed ID: 27533466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
    Massard C; Azaro A; Soria JC; Lassen U; Le Tourneau C; Sarker D; Smith C; Ohnmacht U; Oakley G; Patel BKR; Yuen ESM; Benhadji KA; Rodon J
    Ann Oncol; 2018 Sep; 29(9):1911-1917. PubMed ID: 30060061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma.
    Humtsoe JO; Kim HS; Leonard B; Ling S; Keam B; Marchionni L; Afsari B; Considine M; Favorov AV; Fertig EJ; Kang H; Ha PK
    Cancer Res; 2021 Feb; 81(4):1001-1013. PubMed ID: 33408119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.
    Ho AS; Ochoa A; Jayakumaran G; Zehir A; Valero Mayor C; Tepe J; Makarov V; Dalin MG; He J; Bailey M; Montesion M; Ross JS; Miller VA; Chan L; Ganly I; Dogan S; Katabi N; Tsipouras P; Ha P; Agrawal N; Solit DB; Futreal PA; El Naggar AK; Reis-Filho JS; Weigelt B; Ho AL; Schultz N; Chan TA; Morris LG
    J Clin Invest; 2019 Oct; 129(10):4276-4289. PubMed ID: 31483290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole exome sequencing of adenoid cystic carcinoma.
    Stephens PJ; Davies HR; Mitani Y; Van Loo P; Shlien A; Tarpey PS; Papaemmanuil E; Cheverton A; Bignell GR; Butler AP; Gamble J; Gamble S; Hardy C; Hinton J; Jia M; Jayakumar A; Jones D; Latimer C; McLaren S; McBride DJ; Menzies A; Mudie L; Maddison M; Raine K; Nik-Zainal S; O'Meara S; Teague JW; Varela I; Wedge DC; Whitmore I; Lippman SM; McDermott U; Stratton MR; Campbell PJ; El-Naggar AK; Futreal PA
    J Clin Invest; 2013 Jul; 123(7):2965-8. PubMed ID: 23778141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic heterogeneity and therapeutic target detection through microdissection in solid-type adenoid cystic carcinoma.
    Wang Y; Sun B; Zhang C; Xia R; Sun J; Gu T; Tian Z; Li J
    Pathology; 2022 Aug; 54(5):580-590. PubMed ID: 35337667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.
    de Sousa LG; Neto FL; Lin J; Ferrarotto R
    Curr Oncol Rep; 2022 May; 24(5):621-631. PubMed ID: 35212920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.
    Capone E; Perrotti V; Cela I; Lattanzio R; Togni L; Rubini C; Caponio VCA; Lo Muzio L; Colasante M; Giansanti F; Ippoliti R; Iacobelli S; Wick MJ; Spardy Burr N; Sala G
    Oral Oncol; 2024 Jan; 148():106635. PubMed ID: 37988837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch-1 knockdown suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells.
    Chen W; Cao G; Yuan X; Zhang X; Zhang Q; Zhu Y; Dong Z; Zhang S
    J Transl Med; 2015 May; 13():167. PubMed ID: 25990317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
    Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
    Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of gefitinib in patients with advanced salivary gland cancers.
    Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
    Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
    Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
    Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma.
    Panaccione A; Zhang Y; Ryan M; Moskaluk CA; Anderson KS; Yarbrough WG; Ivanov SV
    Stem Cell Res; 2017 May; 21():160-166. PubMed ID: 28500913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma.
    Liu B; Mitani Y; Rao X; Zafereo M; Zhang J; Zhang J; Futreal PA; Lozano G; El-Naggar AK
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
    Couvreur K; Celine J; Marlies B; Randal D; Philippe D; Frederic D; Sylvie R
    Acta Clin Belg; 2020 Oct; 75(5):362-369. PubMed ID: 31232197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.